Suzhou Keda Technology (603660.SH) announced a forecasted net loss of 120 million to 180 million yuan for the 2024 fiscal year.
Suzhou Keda (603660.SH) issued a notice of annual performance forecast for the year 2024, expecting a loss for the year ended 2024...
Suzhou Keda Technology (603660.SH) announced in its 2024 annual performance forecast that it is expected to incur a net loss attributable to shareholders of the listed company of 120 million to 180 million yuan in 2024, a decrease of 84 million to 144 million yuan compared to the previous year.
In 2024, due to factors such as the domestic macroeconomic environment, the short-term insufficient demand from downstream customers has led to the company's traditional business not recovering as expected. Secondly, the company has adopted a more conservative marketing strategy in some industries or regions in China, controlling the scale of accounts receivable and proactively abandoning projects that may bring risks of accounts receivable repayment. In addition, the company has made certain adjustments to the investment proportion in some businesses and regions, trying to expand more market opportunities outside of the government, which has to some extent affected the company's business income in the traditional core markets. On the expense side, due to the company's continued large investment in research and development in areas such as artificial intelligence and localization, the expenses remain relatively rigid.
Related Articles

HK Stock Market Move | Hong Kong real estate stocks in general have declined. Hang Lung Properties (00101) and Wharf Real Estate Investment Company (01997) both fell by more than 3%.

Stifel raises Coherent's (COHR.US) target price to $275: 6.4T CPO technology shines at OFC 2026.

Bank of France: Johnson & Johnson's new drug enters the psoriasis market, AbbVie's flagship drug Skyrizi faces challenges.
HK Stock Market Move | Hong Kong real estate stocks in general have declined. Hang Lung Properties (00101) and Wharf Real Estate Investment Company (01997) both fell by more than 3%.

Stifel raises Coherent's (COHR.US) target price to $275: 6.4T CPO technology shines at OFC 2026.

Bank of France: Johnson & Johnson's new drug enters the psoriasis market, AbbVie's flagship drug Skyrizi faces challenges.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


